Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules
NCT ID: NCT02765763
Last Updated: 2018-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
45 participants
INTERVENTIONAL
2016-05-31
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Four Topical Products to Improve Skin Longevity
NCT07118943
Efficacy and Tolerance Evaluation of a "Revitalizing" Face Treatment
NCT03276897
Tolerability and Efficacy of Anti-Aging Treatment Regimen in Subjects With Photodamage
NCT02422836
A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects
NCT04276753
RADIESSE Injection in Perioral and Marionette Lines
NCT04172740
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Each participant will test the Test System simultaneously as instructed: The Mask one-to-two times a week plus the Cream and the Serum twice daily (morning and evening); the detailed Directions are shown in Exhibit 2. The test System will be applied directly on face, postauricular and neck skin.
All study subjects will also be provided with Skinfo Clean But Not Dry cleanser and EltaMD UV Pure Broad Spectrum Sun Protective Factor (SPF) 47. Subjects will be instructed to wash their face twice daily with the cleanser and apply the sunscreen each morning after application of the Test System.
Both the study subjects and their physicians will be blinded in terms of the treatment group (the Full Formula or the Null Formula).
Subjects will be screening, consented and enrolled according to Good Clinical Practice.
There will be a 1-week washout of any skin care products deemed to be anti-aging. These products would include any using (as a main ingredient) antioxidants, retinol or retinoid, alpha hydroxyl acid, peptides, growth factors. Any other products that are to continue to be used must have been stable for the last 3 months and must be stable for the 12 weeks of the study.
Before beginning treatment, all participants will undergo medical imaging using the VISIA CA, QuantifiCare imaging system or similar non-invasive visual system. Additionally, their skin will be assessed for transepidermal water loss, wrinkle depth and elasticity (non invasive procedures). Optionally, skin will be tested using non-invasive methods for skin color, hydration, sebum content and will be evaluated using ultrasound scanner (DeremaLab Combo or similar).
Skin evaluation will be also performed at baseline, 6 weeks and 12 weeks using the Griffiths scale (2) as well as the skin evaluation scales for pores, superficial wrinkles, deep or muscle induced wrinkles, and skin radiancy, skin turgor, hyperpigmentation, hypopigmentation, erythema and edema in Blinded Evaluator Skin Assessment (Exhibit 3). The evaluation will be performed in person by the blinded investigators.
Subjects will complete a Consumer Questionnaire (Exhibit 4) at baseline, 6 week and 12 week visits.
Weekly phone calls will be made or emails will be sent (+/- 1 week window) to remind subjects to fill out compliance log, use mask, emphasize cream is applied before the serum. Follow-up appointments reminders will also be sent at this time.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 Sham
Null Formula of the Test System
Null Formula 2-Minute Reveal Masque
Null Formula 24/7 Barrier Repair Cream
Null Formula 8-in-1 BioSerum
Group 2 Treated
Full Formulas of Test System
2-Minute Reveal Masque
24/7 Barrier Repair Cream
8-in-1 BioSerum
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
2-Minute Reveal Masque
24/7 Barrier Repair Cream
8-in-1 BioSerum
Null Formula 2-Minute Reveal Masque
Null Formula 24/7 Barrier Repair Cream
Null Formula 8-in-1 BioSerum
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fitzpatrick Skin Types: I-VI
* Age: 40 - 75 years
* Individuals who will be able to read, understand and give an informed consent relation to the study they are participating in.
* Individuals who will be free of any dermatological or systemic disorder, which in the Principal Investigator's opinion, could interfere with the study results.
* Individuals who will be in general good health and who will complete a preliminary medical history form mandated by the clinic.
* Individuals who will be able to and agree to cooperate with the Investigator and research staff.
* Individuals who will agree to have test products applied in accordance with the protocol and are able to complete the full course of the study.
* Individuals who will agree to have 2 biopsies on the postauricular area if randomly selected.
* Individuals who will agree to not participate in any other study during the entire length of the study and have not participated in a similar study in the past 30 days.
Exclusion Criteria
* Individuals who have a history of any acute or chronic disease that might interfere with or increase the risk on study participation. (e.g., systemic lupus erythematosus, rheumatoid arthritis, HIV positive).
* Individuals who are diagnosed with chronic skin allergies (atopic dermatitis/eczema) or recently treated skin cancer within the last 12 months.
* Individuals who control their diabetes using insulin.
* Individuals with any history, which in the Investigator's opinion, indicates the potential for harm to the subject or places the validity of the study in jeopardy.
* Individuals who indicate that they are pregnant or are planning to become pregnant or nursing.
* Individuals who have undergone any of the following procedures:
* Botox within 6 months before enrollment into study and until study completion
* Injectable filler within 3 months before enrollment into study and until study completion
* Lasers or tissue tightening devices (ultherapy, radiofrequency, skin tightening, microcurrent or photorejuvenation, photodynamic therapy) within 6 months before enrollment into study and until study completion
* Sculptra or Bellafill prior to enrollment into the study and until study completion
40 Years
75 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Advanced Dermatology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amy F Taub, MD
Role: PRINCIPAL_INVESTIGATOR
Advanced Dermatology. LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Advanced Dermatology, LLC
Lincolnshire, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AFT Defenage
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.